Replies to post #380751 on Innovation Pharmaceuticals Inc (IPIX)

[unstable genious 1]

Your" hopefully" overuse is telling...:)

[olden_grumpini]

It's always better to read source documents rather than rely on opinions.

Start by reading the UPenn / Polymedix patent license agreement under which brilacidin was developed. You can read that here: https://www.sec.gov/Archives/edgar/data/1355250/000117152013000616/ex10-20.htm

You should also read the CTIX (now IPIX) response to a SEC request for more information about the Polymedix deal. That response was filed in early 2014 and provided a list of patent expiration dates. You can read that here: https://www.sec.gov/Archives/edgar/data/1355250/000147793214000933/filename1.htm

With those taken care of you will better understand why IPIX includes the following statement in their SEC filings:

All of our Polymedix drug product candidates are licensed from or based upon licenses from the University of Pennsylvania. Upon our purchase of the Polymedix Assets we assumed all contractual rights and obligations of the licenses. If any of these license agreements are terminated, our ability to advance our Polymedix product candidates or develop new product candidates will be materially adversely affected which could have a materially adverse effect on our business.

I've posted several times that my opinion was that IPIX was a good speculative position because of the depressed share price/valuation, massive cash flooding the market, and abundance of uninformed investors.

[Lemoncat]

With regards to antiviral indications and UC indications there is lot of patent remaining. With COVID being our hopeful first-mover for revenue we won't have a patent concern there.

As for as the antimicrobal indications...they aren't worth much anyway so it's not a big deal. If they were we would have partnered up for a phase 3 ABSSSI. Of course, not running that trial, if B-COVID is successful, will have been a $10B+ mistake.

Go IPIX!